c-FLIP is involved in tumor progression of peripheral T-cell lymphoma and targeted by histone deacetylase inhibitors by Zhong Zheng et al.
JOURNAL OF HEMATOLOGY
& ONCOLOGY
Zheng et al. Journal of Hematology & Oncology 2014, 7:88
http://www.jhoonline.org/content/7/1/88RESEARCH Open Accessc-FLIP is involved in tumor progression of
peripheral T-cell lymphoma and targeted by
histone deacetylase inhibitors
Zhong Zheng1†, Shu Cheng1†, Wen Wu1†, Li Wang1,2, Yan Zhao1, Yang Shen1, Anne Janin2,3 and Wei-Li Zhao1,2*Abstract
Background: Peripheral T-cell lymphomas (PTCLs) are often aggressive tumors and resistant to conventional
chemotherapy. Dysregulation of extrinsic apoptosis plays an important role on tumor cell sensitivity to
chemotherapeutic agents. Cellular FLICE inhibitory protein (c-FLIP) is a key regulator of extrinsic apoptotic pathway.
Methods: c-FLIP expression was assessed by real-time PCR and compared according to clinical parameters in
patients with PTCLs. The relation of c-FLIP to tumor cell apoptosis mediated by histone deacetylases inhibitors
(HDACIs) and the possible mechanism were examined in T-lymphoma cell lines and in a murine xenograft model.
Results: c-FLIP was overexpressed and associated with decreased tumor TRAIL/DR5 expression, elevated serum
lactate dehydrogenase level and high-risk International Prognostic Index of the patients. In vitro, molecular silencing
of c-FLIP by specific small-interfering RNA increased TRAIL/DR5 expression, enhanced T-lymphoma cell apoptosis
and sensitized cells to chemotherapeutic agents. However, HDACIs valproic acid (VPA) and suberoylanilide hydroxamic
acid (SAHA) could downregulate c-FLIP expression and triggered extrinsic apoptosis of T-lymphoma cells, through
inhibiting NF-κB signaling and interrupting P50 interaction with c-FLIP promoter. As Class I HDACIs, both VPA and SAHA
inhibited HDAC1, resulting in P50 inactivation and c-FLIP downregulation. In vivo, oral VPA treatment significantly
retarded tumor growth and induced in situ apoptosis, consistent with inhibition of HDAC1/P50/c-FLIP axis and increase
of TRAIL/DR5 expression.
Conclusions: c-FLIP overexpression in PTCLs protected tumor cells from extrinsic apoptosis and contributed to tumor
progression. Although linking to chemoresistance, c-FLIP indicated tumor cell sensitivity to HDACIs, providing a
potential biomarker of targeting apoptosis in treating PTCLs.
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Peripheral T-cell lymphomas (PTCLs) are derived from
malignant proliferation of mature T-lymphocytes and
represent 10%-15% of non-Hodgkin’s lymphomas [1,2].
Compared with B-cell lymphomas, PTCLs are often ag-
gressive and have inferior disease outcome with current
treatment paradigms. Thus, new bio-therapeutic agents* Correspondence: zhao.weili@yahoo.com
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PTCL patients.
Dysregulation of apoptosis is generally implicated in
tumor progression [3,4]. While anti-apoptotic genes of
the intrinsic pathway like BCL-2 and BCL-XL are consti-
tutively activated in their B-cell counterparts [5], T-cell
lymphomas are frequently present with defect in extrin-
sic apoptosis. Cellular FLICE inhibitory protein (c-FLIP)
is a key regulator of extrinsic apoptotic signaling and in-
duces resistance to death receptor-mediated apoptosis
[6]. c-FLIP is overexpressed in tumors of various origins
including non-Hodgkin’s lymphoma and correlated with
poor clinical outcome [7]. However, the expression ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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by therapeutic agents remain largely elusive in PTCLs.
Histone deacetylases inhibitors (HDACIs) constitute a
group of compounds that promote histone acetylation
and transcription of genes involved in multiple cellular
processes including apoptosis [8,9]. Several HDACIs
have been proven effective in treating PTCLs. Recent
studies showed that apoptosis induced by HDACIs in
tumor cells is related to downregulation of c-FLIP and
activation of TNF-related apoptosis-inducing ligand
(TRAIL) signaling [10]. The mode of action of HDACIs
on c-FLIP expression and extrinsic apoptosis needs to be
further investigated in PTCLs.
Cellular transduction pathways play an important role
on cancer cell response to treatment. NF-κB is a major
signaling cascade involved in PTCLs, as revealed by gene
expression profiling [11,12]. Constitutive activation of
NF-κB causes chemoresistance of PTCLs but indicates
tumor cell sensitivity to bio-therapeutic agent like prote-
asome inhibitor Bortezomib [13]. In the present study,
we further addressed the clinical significance of NF-κB
target gene c-FLIP in PTCLs, as well as the molecular
mechanism of HDACIs on c-FLIP modulation and apop-
tosis induction in T-cell lymphoma both in vitro and
in vivo. Functioned as an anti-apoptotic protein of ex-
trinsic pathway, c-FLIP reflected tumor progression and
resistance to chemotherapeutic agents, but could beFigure 1 c-FLIP was overexpressed and related to decreased TRAIL/D
gene (c-FLIPL and c-FLIPS) (A), as well as TRAIL and DR5 expression (B) were
***, P < 0.001 comparing with reactive hyperplasia. All gene expression levelstargeted by HDAC1-mediated NF-κB inactivation and
conferred T-lymphoma cell sensitivity to HDACIs.
Results
c-FLIP was overexpressed and related to tumor
progression in PTCLs
Compared with reactive hyperplasia, long and short
isoform of c-FLIP gene (c-FLIPL and c-FLIPS) were overex-
pressed in patients with PTCLs and T-cell acute lym-
phoblastic leukemia (T-ALL) (P all <0.001, Figure 1A), in
agreement with significant downregulation of extrinsic
apoptosis-inducing signaling ligand TRAIL and its receptor
DR5 (P all <0.001, Figure 1B). Therefore, c-FLIP was poten-
tially an indicator of defective extrinsic apoptosis in PTCLs.
Considering that c-FLIPL was the main isoform ex-
pressed in PTCLs and did not vary from histological sub-
types (Additional file 1: Figure S1), the relation of c-FLIPL
with clinical and biological parameters was studied. The
median expression of c-FLIPL in PTCLs was 70.06. The
patients with c-FLIP expression level over and equal to
the median value were regarded as high c-FLIP expression,
whereas those below the median value were included in
the low c-FLIP expression. Clinically, high c-FLIP ex-
pression was significantly associated with elevated serum
lactate dehydrogenase (LDH) level and International Prog-
nostic Index (IPI) indicating intermediate-high and high-
risk (P = 0.036 and P = 0.010, respectively, Table 1).R5 expression in PTCLs patients. Long and short isoform of c-FLIP
detected by real-time PCR in PTCLs, T-ALL and reactive hyperplasia.
were calculated by ΔΔCT method based on the calibrator Jurkat cells.
Table 1 Clinical and biological characteristics of PTCL
patients (n = 61)
High c-FLIP Low c-FLIP P-value
Age
> 60 years 11 12 0.291
≤ 60 years 19 19
Sex
Female 10 9 0.963
Male 20 22
Ann Arbor stage
I to II 14 13 0.257
III to IV 16 18
Extranodal involvement
No 19 25 0.091
Yes 11 6
Serum LDH level
Normal 11 19 0.036
Abnormal 19 12
IPI score
Low and intermediate low risk 16 25 0.010
Intermediate high and high risk 14 6
Abbreviations: LDH lactate dehydrogenase, IPI International Prognostic Index.
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to chemotherapeutic agents
To better define the biological function of c-FLIP in
PTCLs, Jurkat and H9 cells were transfected with spe-
cific c-FLIP small-interfering RNA (siRNA). The effect
of c-FLIP siRNA on c-FLIP expression was confirmed by
western blot (Figure 2A). Comparing with the control
siRNA (Con siRNA), c-FLIP siRNA resulted in remarkable
induction of tumor cell apoptosis (Figure 2A, P = 0.014
and P = 0.005, respectively), as well as increase of TRAIL
and DR5 expression (Representative results shown in
Figure 2B). Moreover, effects of treatment of both cells
with chemotherapeutic agents such as doxorubicin, cyclo-
phosphamide and cisplatin that are regularly applied to
treat lymphoma, were analyzed by MTT assay and the
concentration of the drug requires for 50% growth inhib-
ition (IC50) was determined. The c-FLIP siRNA trans-
fected cells were more sensitive to these agents than those
transfected with the Con siRNA (P = 0.005, P = 0.015,
P = 0.012 in Jurkat cells and P = 0.002, P = 0.049, P = 0.012
in H9 cells, respectively, Figure 2C), with corresponding
increase of tumor cell apoptosis in c-FLIP siRNA group
(P = 0.021, P = 0.014, P = 0.008 in Jurkat cells and P = 0.012,
P = 0.005, P = 0.020 in H9 cells, respectively, Figure 2D).
These data indicated that c-FLIP conferred tumor cell re-
sistance to chemotherapy.HDACIs induced extrinsic apoptosis and inhibited c-FLIP
expression of T-lymphoma cells
To identify the possible role of bio-therapeutic agents
HDACIs on c-FLIP, Jurkat and H9 cells were cultured
with valproic acid (VPA) and suberoylanilide hydroxamic
acid (SAHA). As shown in Figure 3A, HDACIs exerted
substantial growth inhibition in both cells, which dis-
played characteristic morphological changes of apop-
tosis, such as shrinking cytoplasm, condensed chromatin
and nuclear fragmentation with intact cell membrane
(Figure 3B). Meanwhile, the percentage of Annexin V+/PI+
cells was significantly increased in HDACIs-treated cells
(VPA, P = 0.002 and P = 0.023, SAHA, P = 0.013 and
P = 0.003, respectively, Figure 3C).
HDACIs induced cleavage of Caspase-8, as well as de-
crease of c-FLIP expression both at the protein level
(Figure 3D) and at the transcriptional level (Additional
file 2: Figure S2A, VPA, P = 0.004 and P = 0.008, SAHA,
P < 0.001 and P = 0.008, respectively). Meanwhile, sig-
nificantly increased protein (Figure 3E) and gene expres-
sion of TRAIL and DR5 (Additional file 2: Figure S2B,
TRAIL, VPA, P = 0.004 and P = 0.002, SAHA, P = 0.002
and P = 0.005; DR5, VPA, P = 0.001 and P = 0.012, SAHA,
P = 0.001 and P = 0.009, respectively) were also observed
upon HDACIs treatment, indicating that HDACI-induced
extrinsic apoptosis was associated with downregulation of
c-FLIP. In parallel to c-FLIP overexpression, T-lymphoma
cells were less sensitive to VPA and SAHA, with decreased
percentage of Annexin V+/PI+ cells (VPA, P = 0.031,
SAHA, P = 0.018, respectively) (Figure 3F).
HDACI-mediated c-FLIP downregulation was related to
NF-κB inactivation via interrupting p50 interaction with c-FLIP
c-FLIP is a target gene of NF-κB [14,15]. Extrinsic
apoptosis-related genes, main NF-κB members and NF-κB
target genes were assessed using Human NF-κB Signaling
Pathway Plus PCR Array, before and after VPA or SAHA
treatment (Figure 4A). In according with increased expres-
sion of apoptotic genes, NF-κB members (P65 and P50)
and NF-κB target gene c-FLIP expression were decreased
when treated with HDACIs. As revealed by western blot,
nuclear P65 and P50 expression were downregulated,
along with decrease of phosphorylated IKKα/β (p-IKKα/β)
and phosphorylated IκBα (p-IκBα) expression in HDACI-
treated cells (Figure 4B).
NF-κB member P50 is one of the regulators of c-FLIP
[16]. As detected by immunofluorescence assay, VPA
and SAHA blocked TNF-α-induced nuclear transloca-
tion of P50 in Jurkat and H9 cells (Figure 4C). There-
fore, HDACIs could inhibit both intrinsic and extrinsic
activation of P50. Chromatin immunoprecipitation (CHIP)
assay was subsequently performed to explore the inter-
action of P50 with c-FLIP promoter region. The results
showed that P50 was able to bind with the c-FLIP
Figure 2 Molecular inhibition of c-FLIP induced T-lymphoma cell apoptosis and sensitized tumor cells to chemotherapeutic agents.
A, c-FLIP expression of Jurkat and H9 cells transfected with Con siRNA or c-FLIP siRNA was confirmed by western blot (Left panel). Cell apoptosis
of Jurkat and H9 cells transfected with Con siRNA or c-FLIP siRNA was measured by Annexin-V/PI assay (Right panel). B, TRAIL and DR5 expression
of Jurkat and H9 cells transfected with Con siRNA or c-FLIP siRNA was assessed by flow cytometry. MFI, median fluorescence index. C, IC50 of
doxorubicin, cyclophosphamide and cisplatin using Jurkat cells and H9 cells transfected with Con siRNA or c-FLIP siRNA were determined by MTT
assay after 72 h incubation with chemotherapeutic agents. D, Cell apoptosis of Jurkat cells and H9 cells transfected with Con siRNA or c-FLIP
siRNA was measured by Annexin-V/PI assay after treatment with doxorubicin (75 nm), cyclophosphamide (3 mM) and cisplatin (4 μM) for 72 h,
respectively. *, P < 0.05, **, P < 0.01 comparing with the negative control (Con siRNA).
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treatment, as measured by PCR (Figure 4D). As shown by
luciferase reporter assay, p50 activated the transcriptional
activity of the c-FLIP promoter (P = 0.022, Figure 4E). To
enforce the role of p50, Jurkat cells were transfected with
specific P50 siRNA. The results showed that molecular
silencing of p50 reduced the c-FLIP level (Figure 4F) and
T lymphoma cells were less sensitive to apoptosis (P = 0.021,
Figure 4F). Together, HDACI-induced c-FLIP downregula-
tion was related to inactivation of NF-κB members,
particularly P50.
HDACIs inactivated P50 through inhibiting HDAC1
As Class I HDACIs, VPA inhibited HDAC1 and HDAC3,
whereas SAHA inhibited HDAC1, HDAC2 and HDAC3
expression (Figure 5A). Tissue array (Figure 5B) showedthat HDAC1 was more frequently observed in T-cell
lymphomas than in B-cell lymphomas (83.3% vs 38.9%,
P = 0.016) and correlated with c-FLIP expression (r = 0.795).
This was also present in tumor samples of patients with
PTCLs (P = 0.035, Figure 5C). No significant difference of
other members of Class I HDACIs (HDAC2, HDAC3, and
HDAC8) was observed between T-cell lymphomas and
B-cell lymphomas (data not shown).
Considering that HDAC1 was the main HDAC mem-
ber involved in T-cell lymphomas, further study was fo-
cused on HDAC1 regulation by VPA and SAHA. In
Jurkat and H9 cells, HDACIs-mediated HDAC1 down-
regulation was accompanied by reduced enzymatic ac-
tivity of HDAC1 (VPA, P = 0.037 and P = 0.029, SAHA,
P = 0.047 and P = 0.032, respectively, Figure 5D). More-
over, Jurkat cells were transfected with specific HDAC1
Figure 3 HDACIs triggered extrinsic apoptosis of T-lymphoma cells. A, Cell growth inhibition of Jurkat and H9 cells treated with different
concentrations of HDACIs (VPA and SAHA) for 72 h was determined by MTT assay. B, Representative morphology of Jurkat and H9 cells treated
with VPA (0.5 mM) and SAHA (2 μM) for 72 h was revealed by Wright’s staining. C, Cell apoptosis was measured by Annexin-V/PI assay in Jurkat
and H9 cells treated with VPA (0.5 mM) and SAHA (2 μM) for 72 h. D, Caspase-8, cleaved caspase-8 and c-FLIP expression were detected by
western blot. E, TRAIL and DR5 expression were detected by flow cytometry in Jurkat and H9 cells treated with VPA (0.5 mM) and SAHA (2 μM)
for 72 h. F, c-FLIP expression of Jurkat cells transfected with negative control (NC) or c-FLIP-overexpressing vector (Over) was confirmed by
western blot (Left panel). Cell growth inhibition of these cells treated with different concentrations of HDACIs (VPA and SAHA) for 72 h was
determined by MTT assay (Middle panel). Cell apoptosis of these cells treated with VPA (0.5 mM) and SAHA (2 μM) for 72 h was measured by
Annexin-V/PI assay (Right panel). *, P < 0.05 comparing with the negative control (NC).
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minished HDACIs-mediated inhibition of tumor cell
growth, consistent with decrease of P50 and c-FLIP ex-
pression (Figure 5E and 5F).
HDACIs modulated HDAC1/P50/c-FLIP axis and induced
in situ apoptosis in T-cell lymphoma in vivo
The in vivo anti-tumor activity of HDACIs was further
evaluated in a murine xenograft model of T-cell lymphoma.Subcutaneous inoculation of Jurkat cells into nude mice
resulted in a tumor formation at the site of injection in all
mice. The size of tumors formed in mice treated with oral
VPA was significantly smaller than those of the untreated
group since 12 days of treatment (Day 12, P = 0.049, Day
14, P = 0.012, respectively, Figure 6A).
To search for more evidence of tumor cell apoptosis,
terminal deoxytransferase-catalyzed DNA nick-end la-
beling (TUNEL) assay was performed on mice tumor
Figure 4 HDACI-mediated c-FLIP downregulation was related to NF-κB inactivation via interrupting p50 interaction with c-FLIP.
A, Apoptosis and NF-κB-associated gene expression were detected in Jurkat and H9 cells treated with VPA (0.5 mM) and SAHA (2 μM) for 72 h.
The genes were classified as extrinsic apoptosis-related genes, NF-κB members and NF-κB target gene c-FLIP. B, Nuclear P65 and P50 expression,
as well as whole cell p-IKKαβ, IKKαβ and p-IκBα expression were detected in Jurkat and H9 cells treated with VPA (0.5 mM) and SAHA (2 μM) for
72 h. C, Nuclear P50 expression was evaluated in Jurkat and H9 cells pre-incubated with TNF-α (10 ng/ml) for 4 h and treated with VPA (0.5 mM)
and SAHA (2 μM) for 72 h. D, The activity of P50 binding to the c-FLIP promoter was measured by CHIP assay in Jurkat and H9 cells treated with
VPA (0.5 mM) and SAHA (2 μM) for 72 h. DNA-protein complexes from Jurkat and H9 cells were precipitated with anti-P50 antibody and amplified
with primers for the region of the binding site using PCR (Upper panel). Antibody against RNA Polymerase II was referred as the positive control.
Non-specific Ig and PCR with primers amplifying the distal region of the c-FLIP promoter were referred as the negative control (Lower panel).
E, The effect of P50 on transcriptional activity of the c-FLIP promoter was measured by luciferase reporter assay in HEK-293T cells transfected with
negative control (P50 NC) or P50-overexpressing vector (P50 Over). *, P < 0.05 comparing with the negative control (NC). F, P50 and c-FLIP
expression were detected in Jurkat cells transfected with Con siRNA or P50 siRNA. Cell apoptosis of Jurkat cells transfected with Con siRNA or P50
siRNA was measured. *, P < 0.05 comparing with the negative control (Con siRNA).
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of the apoptotic tumor cells was significantly increased in
the VPA group (P = 0.023, Figure 6B). In according with
in vitro results, P50 (Figure 6C), HDAC1 and c-FLIP ex-
pression (Figure 6D) were decreased, while TRAIL and
DR5 expression (Figure 6D) were increased upon VPA
treatment.
Discussion
Resistance to apoptosis becomes one of the hallmarks of
human cancers [17]. In normal T-lymphocytes, c-FLIPL
and c-FLIPS are expressed to protect T-cells from apop-
tosis [18]. In cutaneous T-cell lymphoma, c-FLIP upreg-
ulation inhibited TRAIL and DR5 expression, resulting
in tumor cell resistance to extrinsic apoptosis [10,19].
Here we showed that c-FLIP is overexpressed in PTCLs
and associated with decreased TRAIL/DR5 expression of
the tumors and adverse clinical parameters of thepatients. This further demonstrated that defective extrin-
sic apoptosis is essential for tumor progression of PTCLs
and the biological behavior of malignant T-cells could
successfully distinguish the clinical heterogeneity of this
disease.
It is well recognized that tumor cells often survive
from chemotherapy via acquiring resistance to apoptosis.
Our experimental data confirmed that anti-apoptotic
c-FLIP contributes to chemoresistance of T-lymphoma
cells, since inhibition of c-FLIP triggered apoptosis
and sensitized tumor cells to chemotherapeutic agents.
Interestingly, difficult to be overcome by chemother-
apy, c-FLIP expression was targeted by HDACIs, con-
sistent with increase of TRAIL/DR5 expression and
subsequent activation of extrinsic apoptosis. Induction
of apoptosis by HDACI has been reported in cutane-
ous T-cell lymphoma and related to downregulation of
c-FLIP and enhanced TRAIL signaling [10]. Therefore,
Figure 5 HDACIs downregulated NF-κB signaling through HDAC1. A, Expression of Class I HDACs including HDAC1, HDAC2, HDAC3 and
HDAC8 were detected by western blot in Jurkat and H9 cells treated with VPA (0.5 mM) and SAHA (2 μM) for 72 h. B, HDAC1 and c-FLIP expression
were determined by tissue array. *, P < 0.05 comparing with B-cell lymphomas. C, HDAC1 expression was evaluated by immunohistochemical study on
tumor sections of PTCLs patients according to c-FLIP expression. The histogram represented the percentage of HDAC1-positive tumors. *, P < 0.05
comparing with low c-FLIP group. D, HDAC1 enzymatic activity was assessed by ELISA in Jurkat and H9 cells treated with VPA (0.5 mM) and SAHA
(2 μM) for 72 h. *, P < 0.05 comparing with the untreated (Control) group. E, Cell growth inhibition of Jurkat cells transfected with Con siRNA or HDAC1
siRNA treated with different concentrations of HDACIs (VPA and SAHA) was determined by MTT assay. *, P < 0.05 comparing with the negative control
(Con siRNA). F, HDAC1, P50 and c-FLIP expression were detected by western blot in Jurkat cells transfected with Con siRNA or HDAC1 siRNA.
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PTCLs, particularly chemoresistant tumors, and c-FLIP
could be a potential biomarker to indicate lymphoma
cell sensitivity to HDACIs.
Cell apoptosis is controlled by NF-κB, mainly as P65
and P50 [20]. P50 acts as a key regulator of NF-κB target
gene c-FLIP [16]. In our study, HDACIs inhibited both
intrinsic and extrinsic activity of P50, interrupted P50
interaction with c-FLIP promoter, and subsequentlydownregulated c-FLIP expression. As mechanism of ac-
tion, HDACI could inactivate NF-κB pathway through
interfering with recruitment of transcription factors to
P50 promoter [21] or blocking IκBα degradation and sub-
sequent nuclear NF-κB translocation [22]. Recent findings
suggested that clinical efficiency of bio-therapeutic agent
targeting NF-κB is independent on P65 expression in
PTCLs patients [23]. Instead, P50 was shown to reflect
tumor cell sensitivity to HDACIs [24]. As the determinant
Figure 6 VPA modulated HDAC1/P50/c-FLIP axis and induced tumor cell apoptosis in a murine xenograft T-lymphoma model. A, The
tumor growth curve of the Control group and the VPA group (0.4%w/v in the drinking water daily) in murine xenograft model established with
subcutaneous injection of Jurkat cells. B, In situ apoptosis of the Control group and the VPA group was assessed by TUNEL assay. *, P < 0.05
comparing with the untreated (Control) group. C, P50 expression of the Control group and the VPA group was detected by western blot.
D, HDAC1, c-FLIP, TRAIL and DR5 expression were evaluated by immunohistochemical study in the Control group and the VPA group.
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closely related to HDACIs-mediated apoptosis and c-FLIP
downregulation in PTCLs.
Increased Class I HDAC activity and expression are
associated with NF-κB activation of tumor cells [25]. As
the major HDAC in PTCLs [26], both protein expression
and enzymatic activity of HDAC1 were reduced upon
treatment with Class I HDACIs like VPA and SAHA
[27,28]. Molecular silencing of HDAC1 by siRNA mim-
icked the effect of HDACIs on tumor cell growth, as
well as on P50 and c-FLIP downregulation. Therefore,
HDAC1 could function as the action site of VPA and
SAHA in PTCLs. It is previously reported that in acute
myeloid leukemia [16], HDAC1 is displaced from P50
homodimers bound to anti-apoptotic genes, contributing
to NF-κB inactivation and c-FLIP downregulation. In
glioblastoma, another transcription factor c-myc could
be recruited on c-FLIP promoter upon HDACI treat-
ment and resulted in decreased expression of c-FLIP
[29]. Our study showed that VPA and SAHA induced
lymphoma cell apoptosis through inactivating HDAC1/
P50/c-FLIP axis, indicative an alternative mechanism ofHDACIs on NF-κB activation and tumor cell apoptosis
in PTCLs.
c-FLIP inhibited extrinsic apoptosis and favored tumor
progression, providing a therapeutic target in PTCLs.
HDACIs are convictive as apoptosis-inducing agents in
PTCLs, either alone or combined with other agents
[9,30,31]. HDAC1/P50/c-FLIP axis could thus be helpful
to determine clinical efficiency of HDACIs.
Conclusions
Our findings highlighted that c-FLIP was involved in de-
fective apoptosis, tumor progression in PTCLs and re-
lated to T-lymphoma cell apoptosis induced by HDACIs
through inhibiting HDAC1/P50/c-FLIP axis.
Methods
Patients
Sixty-one patients diagnosed as PTCLs were enrolled in
this study, including PTCL-not otherwise specified (33
cases), angioimmunoblastic T-cell lymphoma (16 cases),
and anaplastic large-cell lymphoma (12 cases). Histologic
diagnoses were established according to the World Health
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consisted of 6 to 8 cycles of CHOP or CHOP-like regimen.
The clinical and biological features of the patients were
listed in Table 1. Twenty cases with T-ALL and thirty
cases with reactive hyperplasia were referred as controls.
The study was approved by the Shanghai Rui Jin Hospital
Review Board with informed consent obtained from all pa-
tients in accordance with the Declaration of Helsinki.
Cells and reagents
T lymphoma cell lines (Jurkat and H9) and HEK-293
T cells were obtained from American Type Culture
Collection (Manassas, VA, USA). Cells were cultured
in RPMI-1640 medium supplemented with 10% heat-
inactivated fetal bovine serum in humidified atmosphere
of 95% air and 5% CO2 at 37°C. VPA was from Sigma-
Aldrich (St Louis, MO, USA). SAHA was from Merck &
Co (Darmstadt, Germany). Antibodies against Caspase-8,
p-IKKα/β, p-IκBα and HDAC3 were purchased from Cell
Signaling (Beverly, MA, USA). Antibodies against c-FLIP,
P65, P50, IKKα/β, IκBα, HDAC1, HDAC2, HDAC8 and
Lamin B were from Abcam (Cambridge, UK). Anti-β-
actin antibody was from Sigma-Aldrich. Horseradish
peroxidase-conjugated goat anti-mouse IgG and goat anti-
rabbit IgG were from Santa Cruz Biotechnology (Santa
Cruz, CA, USA).
Cell proliferation and morphology
Cell proliferation was assessed by MTT assay and the
absorbance was measured at 490 nm by spectrophotom-
etry. Cell morphology was evaluated by Wright’s staining
under light microscopy.
Flow cytometric assay
Cell apoptosis was assessed using Annexin V-FITC
Apoptosis Kits (Becton Dickinson, Franklin Lakes, NJ,
USA) according to the manufacturer’s instructions. Ex-
pression levels of TRAIL and DR5 were quantified using
antibodies against TRAIL (Cell signaling) and DR5
(Abnova, Walnut, CA, USA) as the primary antibodies,
and DyLight 405 labeled anti-rabbit antibody (KPL,
Washington DC, USA) as the secondary antibody. The
median fluorescent intensity (MFI) was measured by
flow cytometry.
Real-time polymerase chain reaction (PCR)
Total RNA was extracted from frozen tissue of PTCLs
and reactive hyperplasia, as well as bone marrow blasts
of T-ALL, using TRIzol reagent (Invitrogen). cDNA was
synthesized using PrimeScript RT reagent Kits with
gDNA Eraser (TaKaRa, CA, USA) following the manu-
facturer’s instructions. Real-time polymerase chain reac-
tion (PCR) was performed using SYBR Premix Ex Taq™
II (TaKaRa) on ABI Prism 7500 (Applied Biosystems,Bedford, MA, USA). The relative gene expression levels
were calculated using the SDS2.4 software. The primer
sequences were as follows: c-FLIPL forward, 5′-ATTG
CATTGGCAATGAGACAGAGC-3′; reverse, 5′-TCGG
TGCTCGGGCATACAGG-3′, c-FLIPS forward, 5′-ACC
CTCACCTTGTTTCGGACTAT-3′; reverse, 5′-TGAGG
ACACATCAGATTTATCCAAA-3′, TRAIL forward, 5′-
TCAGCACTTCAGGATGATGG-3′; reverse, 5′-CACC
AGCTGTTTGGTTCTCA-3′, DR5 forward, 5′-TGACG
GGGAAGAGGAACTGA-3′; reverse, 5′-GGCTTTGAC
CATTTGGATTTGA-3′, GAPDH forward, 5′-GAAGGT
GAAGGTCGGAGTC-3′; reverse, 5′-GAAGATGGTGA
TGGGATTTC-3′.
Real-time PCR of NF-κB signaling pathway was per-
formed using the RT2 profiler PCR Array-Human NF-κB
signaling pathway (QIAGEN Sciences, Frederick, MD,
USA). GAPDH was used as the endogenous control and
Jurkat cells for calibration. A relative quantification was
calculated using the ΔΔCT method.Tissue array
A human lymphoma tissue array was purchased from US
Biomax, Inc. (Rockville, MD, USA) containing 12 T-cell
lymphomas and 18 B-cell lymphomas. Levels of protein
expression were graded according to staining intensity (SI)
and distribution using the immunoreactive score (IRS).
IRS = SI × PP (percentage of positive cells). SI was defined
as 0 = negative; 1 = weak; 2 =moderate; and 3 = strong. PP
was scored as 1, <25%; 2, 25-50%; 3, 50-75%; and 4, 75-
100% positive cells. IRS > 4 was determined as positive.Immunohistochemistry and immunofluorescence assay
Immunohistochemistry was performed on 5 μm-paraffin
sections with an indirect immunoperoxidase method
using the primary antibody against c-FLIP (1:200), TRAIL
(1:800), DR5 (1:200), HDAC1 (1:100), HDAC2 (1:100),
HDAC3 (1:100) and HDAC8 (1:100). Immunofluorescence
assay was performed on methanol-fixed cells using P50 as
the primary antibody and diaminotriazinylaminofluorescein-
labeled donkey anti-rabbit-IgG antibody (Abcam) as the
second antibody.Cell transfection
Jurkat cells were transfected with c-FLIP, P50 and
HDAC1 siGENOME SMARTpool or Non-Targetingpool
(Dharmacon) as the negative control using Dharma-
FECT2 transfection reagent (Dharmacon) following the
manufacturer’s instruction. As for overexpression assay,
Jurkat cells were transfected with c-FLIP-overexpressing
vector or a control vector, electroporated at 250 V 25
ms in 4-mm cuvettes using a BTX ECM 830 and
replated in fresh medium for further experiments.
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Cells were suspended in 400 μL lysis buffer (10 mM
HEPES, 10 mM KCl, 1.5 mM MgCl2, 0.5 mM DTT,
pH 7.9) with 0.2% Nonidet P-40 and protease inhibitor
cocktail for 1 min on ice. After centrifuged for 1 min at
2500 × g, the supernatants were collected as cytoplasmic
protein extracts. The pellets were washed with lysis buf-
fer without Nonidet P-40, then re-suspended in 150 μL
extraction buffer (20 mM HEPES, pH 7.9, 420 mM
NaCl, 0.5 mM DTT, 0.2 mM EDTA and 25% glycerol),
and incubated for 20 min on ice. After centrifuged at
12000 × g for 10 min, the supernatants were collected as
nuclear protein extracts.
Western blot
Cells were collected and lysed in 200 μL lysis buffer
(Sigma Aldrich). Protein lysates (20 μg) were electropho-
resed on 10% sodium dodecyl sulfate polyacrylamide gels
and transferred to nitrocellulose membranes. Mem-
branes were blocked with 5% non-fat dried milk and
incubated overnight at 4°C with appropriate primary
antibody, followed by horseradish peroxidase-linked sec-
ondary antibody. The immunocomplexes were visualized
using chemiluminescence phototope-horseradish perox-
idase Kits. Lamin B and β-actin were used to ensure
equivalent loading of nuclear and whole cell protein,
respectively.
CHIP assay
CHIP assay was performed using EZ-ChIP Kits (Millipore,
Billerica, MA, USA) to identify the interaction between
DNA and protein following the manufacturer’s instruc-
tions. Antibody against RNA Polymerase II was referred
as the positive control and non-specific Ig and PCR with
primers amplifying the distal region of the c-FLIP pro-




HEK-293T cells were transfected with luciferase reporter
and P50 overexpressing vector, using Lipofectamine
2000 (Invitrogen) according to the manufacturer’s in-
structions. Protein was collected 24 h after transfection,
using the Passive Lysis Buffer (30 μL per well) provided
as part of the Dual-Luciferase Reporter Assay System kit
(Promega). Firefly and Renilla luciferase activities were
examined by the Dual-Luciferase Reporter Assay System
and detected by a Centro XS3 LB960 Luminometer
(Berthold).
Enzyme-linked immunosorbent assay
Enzymatic activity of HDAC1 was quantified by enzyme-
linked immunosorbent assay using HDAC colorimetricKit (BioVision, Milpitas, CA, USA) according to the
manufacturer’s instructions.TUNEL assay
In situ cell apoptosis was determined by detection of
fragmented DNA, using DeadEnd Colorimetric Terminal
deoxytransferase-catalyzed DNA nick-end labeling Sys-
tem (Promega Corporation, Madison, WI, USA), on
5 μm-paraffin sections according to the manufacturer’s
instructions.Murine model
To test the in vivo efficiency of VPA, nude mice (5-6-
week-old, obtained from Shanghai Laboratory Animal
Center, Shanghai, China) were injected with 4 × 107 Jurkat
cells into the right flank. Treatments started after tumor
became about 0.5 cm× 0.5 cm in surface (Day 0). The
control group received saline, the treatment group re-
ceived oral VPA for 14 days (0.4%w/v in the drinking
water daily).Statistical analysis
Difference of c-FLIP expression among groups were cal-
culated using Mann–Whitney U test. The association
between c-FLIP expression and clinical parameters was
analyzed by Chisquare test. In vitro experimental results
were expressed as mean±s.d. of data obtained from three
separate experiments and determined by t-test to com-
pare variance. P<0.05 was considered to be significant.
Statistical analyses were performed on SPSS13.0 software.Additional files
Additional file 1: Figure S1. c-FLIP expression according to histologic
subtypes of PTCLs. Elevated c-FLIP levels were observed among all the
PTCL subtypes studied, including PTCL-not otherwise specified (PTCL-NOS),
angioimmunoblastic T-cell lymphoma (AITCL), and anaplastic large-cell
lymphoma (ALCL).
Additional file 2: Figure S2. Extrinsic apoptotic gene expressions
during HDACIs treatment in T-lymphoma cells. The expression of c-FLIP
(A), TRAIL and DR5 (B) were detected by real-time PCR in Jurkat and H9
cells treated with VPA (0.5 mM) and SAHA (2 μM) for 72 h. ***, P < 0.001,
**, P < 0.01, comparing with the untreated (Control) group.Abbreviations
PTCLs: Peripheral T-cell lymphomas; HDACIs: Histone deacetylase inhibitors;
VPA: Valproic acid; SAHA: Suberoylanilide hydroxamic acid; c-FLIP: Cellular
FLICE inhibitory protein; TRAIL: TNF-related apoptosis-inducing ligand;
T-ALL: T-cell acute lymphoblastic leukemia; LDH: Serum lactate
dehydrogenase; IPI: International prognostic index; siRNA: Small-interfering
RNA; CHIP: Chromatin immunoprecipitation; TUNEL: Terminal
deoxytransferase-catalyzed DNA nick-end labeling.Competing interests
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